AIMS Cancer Outcomes Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorAdvanced Integrative Medical Science Institute
About this trial
The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect data and study outcomes for patients with cancer who receive care at AIMS Institute.
Eligibility criteria
Qualifiers
A new patient coming in for a first office call (FOC) or first consultation via telemedicine with a diagnosis of cancer, or
An established patient with a diagnosis of cancer receiving treatment at the AIMS Institute;
If over 18 years of age are able to understand study design adequately and provide signed informed consent (IC) to enrollment;
If younger than 18 years of age informed assent from the child and informed consent from a parent or guardian who is able to understand the study design adequately and provide signed informed consent for the pediatric patient;
Disqualifiers
Patients not diagnosed with cancer;
Telehealth patients;
Cannot read or understand English well enough to read and sign the consent form and complete the questionnaires;
Unwilling to participate in the AIMS Institute observational study.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov